Bandaríkin - enska - NLM (National Library of Medicine)

harrow eye, llc - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae , klebsiella /enterobacter species, neisseria species, and pseudomonas aeruginosa . this product does not provide adequate coverage against: serratia marcescens and s treptococci , including streptococcus pneumoniae . maxitrol ® (neomycin and polymyxin b sulfates and dexamethasone ophthalmic suspension) is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. maxitrol is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - dexamethasone; neomycin sulfate; polymyxin b sulfate - eye ointment - 1mg/1gram ; 3500unit/1gram ; 6000unit/1gram

Írland - enska - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - neomycin sulfate, polymyxin b sulfate, dexamethasone - eye ointment - corticosteroids and antiinfectives in combination

Bandaríkin - enska - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitises is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drugs in this product is active against the following common bacterial eye pathogens: staphylococcus aureus , escherichia coli, haemophilus influenzae , klebsi

Bandaríkin - enska - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/e

Bandaríkin - enska - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/enterobacter s

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dexamethasone 1 mg/g (3 % overage);  ; neomycin sulfate 3500 iu/g; polymyxin b sulfate 6000 iu/g - eye ointment - active: dexamethasone 1 mg/g (3 % overage)   neomycin sulfate 3500 iu/g polymyxin b sulfate 6000 iu/g excipient: lanolin methyl hydroxybenzoate propyl hydroxybenzoate white soft paraffin - maxitrol is indicated in ocular inflammation when concurrent use of an antimicrobial is judged necessary.

Ísrael - enska - Ministry of Health

teva pharmaceutical industries ltd, israel - dexamethasone sodium phosphate; neomycin sulfate; polymyxin b sulfate - drops - dexamethasone sodium phosphate 1 mg/ml; neomycin sulfate 5 mg/ml; polymyxin b sulfate 10000 u/ml - dexamethasone and antiinfectives - dexamethasone and antiinfectives - inflammatory conditions, superficial bacterial infections.

Bandaríkin - enska - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/enterobacter

Bandaríkin - enska - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae , klebsiella